The scientific goals of the Experimental and Developmental (EDT) Program are to: 1) Discover and validate novel therapeutic targets;2) Identify new therapeutic agents and approaches, and 3) Conduct early phase translational clinical trials of novel therapies. The EDT Program is comprised of 25 members from two schools at the University of Texas Health Science Center at San Antonio (UTHSCSA) and one college at the University of Texas at San Antonio (UTSA). The EDT membership represents 11 departments and has been recruited from notable institutions including Harvard Medical School, MD Anderson Cancer Center and UT Southwestern. The EDT Program members have a wide range of expertise, from synthetic organic chemistry and structural biology, through lead identification and IND-enabling studies, obtaining an IND, to conducting clinical trials. These complementary areas of expertise provide the opportunities for cutting-edge translational research. Seven Program members are clinician scientists, physicians, or dentists who provide a strong translational focus to the program. The Co-Leaders, Drs. Weitman and Mooberry have complementary areas of expertise and interests to span the entire range of activities of the Program. In the past budget year, EDT members received a total of $2,150,045 of NCI funding (11 grants) and an additional $2,723,945 (15 grants) of other peer-reviewed cancer-related grant support. The EDT Program has 177 peer-reviewed cancer related publications of which 89 (50%) are intra-programmatic collaborations and 26 (15%) are inter-programmatic collaborations.

Public Health Relevance

The Experimental and Developmental Therapeutics (EDT) Program takes the lead in the Cancer Therapy & Research Center's effort to develop and test new treatments for cancer. It is an integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the treatment of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center
San Antonio
United States
Zip Code
Chalela, P; Munoz, E; Inupakutika, D et al. (2018) Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. Contemp Clin Trials Commun 12:109-115
Chalela, Patricia; Muñoz, Edgar; Gallion, Kipling J et al. (2018) Empowering Latina breast cancer patients to make informed decisions about clinical trials: a pilot study. Transl Behav Med 8:439-449
Weiner, Marc; Gelfond, Jon; Johnson-Pais, Teresa L et al. (2018) Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother 62:
Liu, Jinyou; Sareddy, Gangadhara R; Zhou, Mei et al. (2018) Differential Effects of Estrogen Receptor ? Isoforms on Glioblastoma Progression. Cancer Res 78:3176-3189
Chakravarthy, Divya; Muñoz, Amanda R; Su, Angel et al. (2018) Palmatine suppresses glutamine-mediated interaction between pancreatic cancer and stellate cells through simultaneous inhibition of survivin and COL1A1. Cancer Lett 419:103-115
Van Skike, Candice E; Jahrling, Jordan B; Olson, Angela B et al. (2018) Inhibition of mTOR protects the blood-brain barrier in models of Alzheimer's disease and vascular cognitive impairment. Am J Physiol Heart Circ Physiol 314:H693-H703
Cooney, Jeffrey D; Lin, An-Ping; Jiang, Daifeng et al. (2018) Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K? in Mature B-cell Malignancies. Clin Cancer Res 24:1103-1113
Zhu, Haiyan; Gu, Xiang; Xia, Lu et al. (2018) A Novel TGF? Trap Blocks Chemotherapeutics-Induced TGF?1 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers. Clin Cancer Res 24:2780-2793
Bandyopadhyay, Abhik; Favours, Edward; Phelps, Doris A et al. (2018) Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models. Pediatr Blood Cancer 65:
Azpurua, Jorge; Mahoney, Rebekah E; Eaton, Benjamin A (2018) Transcriptomics of aged Drosophila motor neurons reveals a matrix metalloproteinase that impairs motor function. Aging Cell 17:

Showing the most recent 10 out of 989 publications